Ozempic Dosage Guide
Ozempic (semaglutide) is FDA-approved for glycemic control in type 2 diabetes and to reduce cardiovascular events in patients with established CV disease. Maximum approved weekly dose: 2.0 mg[FDA PI].
Ozempic Titration Schedule
| Weeks | Dose | Pen | Phase |
|---|---|---|---|
| 1 – 4 | 0.25 mg / wk | 0.25/0.5 mg pen | Starter (not therapeutic) |
| 5 – 8 | 0.5 mg / wk | 0.25/0.5 mg pen | Maintenance (option A) |
| 9+ (if needed) | 1.0 mg / wk | 1 mg pen | Maintenance (option B) |
| Additional escalation | 2.0 mg / wk | 2 mg pen | If 1.0 mg insufficient |
Source: Ozempic FDA prescribing information (Novo Nordisk). Ozempic 2 mg/week approved in March 2022.
Choosing the right pen
Ozempic is supplied in three pen strengths. Each pen delivers a single weekly dose at the dialed level.
- 0.25/0.5 mg pen: delivers either 0.25 mg or 0.5 mg per dose. Used for weeks 1–8 and ongoing maintenance at 0.5 mg.
- 1 mg pen: delivers a single 1 mg dose. Used for maintenance at 1 mg/week.
- 2 mg pen: delivers a single 2 mg dose. Used for escalated maintenance when 1 mg is inadequate.
Key differences vs other semaglutide formulations
- vs Wegovy: Same molecule. Different indication (diabetes vs weight loss) and different max dose (2.0 mg vs 2.4 mg weekly). Ozempic titration stops earlier.
- vs Rybelsus: Injection vs oral tablet. Bioavailability of oral semaglutide is much lower (~1%), requiring much higher mg doses (14 mg daily) to achieve similar plasma levels.
- vs Trulicity (dulaglutide): Different GLP-1 agonists. Ozempic typically produces greater glycemic and weight effects at equivalent titration steps (SUSTAIN 7 trial).
- vs Mounjaro (tirzepatide): Different molecule — tirzepatide is a dual GLP-1/GIP agonist. Head-to-head trials (SURPASS-2) showed greater HbA1c and weight reduction with tirzepatide.
Dosage adjustments
Renal: no dose adjustment for mild–severe renal impairment. Caution in ESRD — limited safety data. Hepatic: no adjustment. Pediatric: Ozempic is not approved for patients under 18. Geriatric: no adjustment needed, but monitor for dehydration from GI effects.
Ozempic side effects by dose
- 0.25 mg (starter): mild nausea in ~15–20% of patients, usually resolves in 7–10 days.
- 0.5 mg: modest appetite suppression. GI effects usually mild by this point.
- 1 mg: strongest glycemic control for most patients. Nausea may recur briefly after step-up.
- 2 mg: additional HbA1c reduction (~0.3% over 1 mg in SUSTAIN FORTE). GI effects may be slightly increased but generally tolerable in patients who tolerated 1 mg.
Boxed warning: Risk of thyroid C-cell tumors (based on rodent studies). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[FDA PI].
References
- Ozempic (semaglutide) FDA prescribing information. Current label PDF · Drugs@FDA overview (NDA 209637)
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM 2016; 375:1834–44. NEJM · PubMed 27633186
- Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs 1.0 mg in Patients with Type 2 Diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol 2021; 9:563–74. PubMed 34293304
- All SUSTAIN trials (search). PubMed